RMD Stock Recent News
RMD LATEST HEADLINES
ResMed beat Wall Street estimates for quarterly profit on Wednesday due to strong demand for its sleep apnea devices, sending shares 9% higher in extended trading.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Investors are optimistic about ResMed (RMD) led by the strong uptake of the myAir app with Air 11 systems.
ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.
ResMed (RMD) reported earnings 30 days ago. What's next for the stock?
Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.
ResMed's (RMD) new AirCurve11 series incorporates MyAir and AirView digital health apps to provide maximum comfort and support during therapy.
ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.